Role of DNA-dependent protein kinase catalytic subunit in cancer development and treatment

Translational Cancer Research

Volumn 1, Issue 1, 2012, Pages 22-34

  Hsu, Feng Ming ^a   Zhang, Shichuan ^b   Chen, Benjamin P C ^c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b SICHUAN CANCER HOSPITAL   (China)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti DNA PKcs strategies; Carcinogenesis; DNA damage

Indexed keywords

CISPLATIN; DNA DEPENDENT PROTEIN KINASE;

CANCER SUSCEPTIBILITY; CANCER THERAPY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENOMIC INSTABILITY; GERMLINE MUTATION; HUMAN; IMMUNOCOMPETENCE; IN VITRO STUDY; LETHALITY; LYMPHOMA; MALIGNANT NEOPLASM; RADIOSENSITIZATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84962662283     PISSN: 2218676X     EISSN: 22196803     Source Type: Journal    
DOI: 10.3978/j.issn.2218-676X.2012.04.01     Document Type: Review

References (109)

1. Mahaney BL, Meek K, Lees-Miller SP. Repair of ionizing radiation-induced DNA double-strand breaks by nonhomologous end-joining. Biochem J 2009;417:639-50.
2. Weterings E, Chen DJ. The endless tale of nonhomologous end-joining. Cell Res 2008;18:114-24.
3. Blunt T, Gell D, Fox M, et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNAdependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci USA 1996;93:10285-90.
4. Gao Y, Chaudhuri J, Zhu C, et al. A targeted DNA-PKcsnull mutation reveals DNA-PK-independent functions for KU in V(D)J recombination. Immunity 1998;9:367-76.
5. Kurimasa A, Ouyang H, Dong LJ, et al. Catalytic subunit of DNA-dependent protein kinase: impact on lymphocyte development and tumorigenesis. Proc Natl Acad Sci USA 1999;96:1403-8.
6. Chen BP, Uematsu N, Kobayashi J, et al. ATM is essential for DNA-pkcs phosphorylations at T2609 cluster upon DNA double strand break. J Biol Chem 2007;282:6582-7.
7. Ding Q, Reddy YV, Wang W, et al. Autophosphorylation of the catalytic subunit of the DNA-dependent protein kinase is required for efficient end processing during DNA doublestrand break repair. Mol Cell Biol 2003;23:5836-48.
8. Nagasawa H, Little JB, Lin YF, et al. Differential role of DNA-PKcs phosphorylations and kinase activity in radiosensitivity and chromosomal instability. Radiat Res 2011;175:83-9.
9. Reddy YV, Ding Q, Lees-Miller SP, et al. Nonhomologous end joining requires that the DNAPK complex undergo an autophosphorylationdependent rearrangement at DNA ends. J Biol Chem 2004;279:39408-13.
10. Yajima H, Lee KJ, Chen BP. ATR-dependent phosphorylation of DNA-dependent protein kinase catalytic subunit in response to UV-induced replication stress. Mol Cell Biol 2006;26:7520-8.
11. Chen BP, Chan DW, Kobayashi J, et al. Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks. J Biol Chem 2005;280:14709-15.
12. Lee KJ, Lin YF, Chou HY, et al. Involvement of DNAdependent protein kinase in normal cell cycle progression through mitosis. J Biol Chem 2011;286:12796-802.
13. Shang ZF, Huang B, Xu QZ, et al. Inactivation of DNAdependent protein kinase leads to spindle disruption and mitotic catastrophe with attenuated checkpoint protein 2 Phosphorylation in response to DNA damage. Cancer Res 2010;70:3657-66.
14. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-9.
15. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature 1997;386:761, 3.
16. O'Driscoll M, Gennery AR, Seidel J, et al. An overview of three new disorders associated with genetic instability: LIG4 syndrome, RS-SCID and ATR-Seckel syndrome. DNA Repair (Amst) 2004;3:1227-35.
17. Jeggo PA. Genomic instability in cancer development. Adv Exp Med Biol 2005;570:175-97.
18. Hosoi Y, Watanabe T, Nakagawa K, et al. Up-regulation of DNA-dependent protein kinase activity and Sp1 in colorectal cancer. Int J Oncol 2004;25:461-8.
19. Lü Y, Zhang HL, Li YZ, et al. [Clinicopathological significance of expressions of DNA dependent protein kinase catalytic subunit and P16 in colorectal carcinoma]. Zhonghua Yi Xue Za Zhi 2008;88:2025-9.
20. Tonotsuka N, Hosoi Y, Miyazaki S, et al. Heterogeneous expression of DNA-dependent protein kinase in esophageal cancer and normal epithelium. Int J Mol Med 2006;18:441-7.
21. Yan SS, Liu L, Liu ZG, et al. Expression and clinical significance of DNA-PKcs in nasopharyngeal carcinoma. Ai Zheng 2008;27:979-83.
22. Lee S-W, Cho K-J, Park J-H, et al. Expressions of Ku70 and DNA-PKcs as prognostic indicators of local control in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2005;62:1451-7.
23. Pan H, Zuo C, Mao N, et al. [Expression and clinical significance of Ku70, Ku80 and DNA-PKcs proteins in patients with stageI-II non-small cell lung cancer by tissue microarray.]. Zhongguo Fei Ai Za Zhi 2007;10:203-5.
24. Xing J, Wu X, Vaporciyan AA, et al. Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. Cancer 2008;112:2756-64.
25. Yu S, Xiong Y, Tian S. [The expression of DNA-PKcs in non-small cell lung cancer and its relationship with apoptosis associated proteins.]. Zhongguo Fei Ai Za Zhi. 2003;6:356-9.
26. Hao Y, Hu X, Liu Y, et al. [The expression of ERCC1, DNA-PKcs protein and the relation to prognosis in non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi. 2008;11:226-30.
27. Shao CJ, Fu J, Shi HL, et al. Activities of DNA-PK and Ku86, but not Ku70, may predict sensitivity to cisplatin in human gliomas. J Neurooncol 2008;89:27-35.
28. Mukherjee B, McEllin B, Camacho CV, et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 2009;69:4252-9.
29. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
30. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
31. Lee HS, Yang HK, Kim WH, et al. Loss of DNAdependent protein kinase catalytic subunit (DNAPKcs) expression in gastric cancers. Cancer Res Treat 2005;37:98-102.
32. Lee HS, Choe G, Park KU, et al. Altered expression of DNA-dependent protein kinase catalytic subunit (DNAPKcs) during gastric carcinogenesis and its clinical implications on gastric cancer. Int J Oncol 2007;31:859-66.
33. Gologan A, Graham DY, Sepulveda AR. Molecular markers in Helicobacter pylori-associated gastric carcinogenesis. Clin Lab Med 2005;25:197-222.
34. Shao SL, Cai Y, Wang QH, et al. Expression of GLUT-1, p63 and DNA-Pkcs in serous ovarian tumors and their significance. Zhonghua Zhong Liu Za Zhi 2007;29:697-700.
35. Auckley DH, Crowell RE, Heaphy ER, et al. Reduced DNA-dependent protein kinase activity is associated with lung cancer. Carcinogenesis 2001;22:723-7.
36. Someya M, Sakata K, Matsumoto Y, et al. The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer. Carcinogenesis 2006;27:117-22.
37. Someya M, Sakata KI, Matsumoto Y, et al. The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer. Br J Cancer 2011;104:1724-9.
38. Someya M, Sakata K, Matsumoto Y, et al. Association of DNA-PK activity and radiation-induced NBS1 foci formation in lymphocytes with clinical malignancy in breast cancer patients. Oncol Rep 2007;18:873-8.
39. Noguchi T, Shibata T, Fumoto S, et al. DNA-PKcs expression in esophageal cancer as a predictor for chemoradiation therapeutic sensitivity. Ann Surg Oncol 2002;9:1017-22.
40. Söderlund Leifler K, Queseth S, Fornander T, et al. Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol 2010;37:1547-54.
41. Shintani S, Mihara M, Li C, et al. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci 2003;94:894-900.
42. Beskow C, Skikuniene J, Holgersson A, et al. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br J Cancer 2009;101:816-21.
43. Manis JP, Dudley D, Kaylor L, et al. IgH class switch recombination to IgG1 in DNA-PKcs-deficient B cells. Immunity 2002;16:607-17.
44. Cook AJ, Oganesian L, Harumal P, et al. Reduced switching in SCID B cells is associated with altered somatic mutation of recombined S regions. J Immunol 2003;171:6556-64.
45. Holgersson A, Erdal H, Nilsson A, et al. Expression of DNA-PKcs and Ku86, but not Ku70, differs between lymphoid malignancies. Exp Mol Pathol 2004;77:1-6.
46. Muller C, Christodoulopoulos G, Salles B, et al. DNADependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. Blood 1998;92:2213-9.
47. Willmore E, Elliott SL, Mainou-Fowler T, et al. DNAdependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008;14:3984-92.
48. Elliott SL, Crawford C, Mulligan E, et al. Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia. Br J Haematol 2011;152:61-71.
49. Eriksson A, Lewensoh R, Larsson R, et al. DNAdependent protein kinase in leukaemia cells and correlation with drug sensitivity. Anticancer Res 2002;22:1787-93.
50. Wang X, Szabo C, Qian C, et al. Mutational analysis of thirty-two double-strand DNA break repair genes in breast and pancreatic cancers. Cancer Res 2008;68:971-5.
51. Chan DW, Chen BP, Prithivirajsingh S, et al. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks. Genes Dev 2002;16:2333-8.
52. Zhang S, Yajima H, Huynh H, et al. Congenital bone marrow failure in DNA-PKcs mutant mice associated with deficiencies in DNA repair. J Cell Biol 2011;193:295-305.
53. van der Burg M, Ijspeert H, Verkaik NS, et al. A DNAPKcs mutation in a radiosensitive T-B-SCID patient inhibits Artemis activation and nonhomologous endjoining. J Clin Invest 2009;119:91-8.
54. Wang SY, Peng L, Li CP, et al. Genetic variants of the XRCC7 gene involved in DNA repair and risk of human bladder cancer. Int J Urol 2008;15:534-9.
55. Long XD, Yao JG, Huang YZ, et al. DNA repair gene XRCC7 polymorphisms (rs#7003908 and rs#10109984) and hepatocellular carcinoma related to AFB1 exposure among Guangxi population, China. Hepatol Res 2011;41:1085-93.
56. Hu Z, Liu H, Wang H, et al. Tagging single nucleotide polymorphisms in phosphoinositide-3-kinase-related protein kinase genes involved in DNA damage "checkpoints" and lung cancer susceptibility. Clin Cancer Res 2008;14:2887-91.
57. Durant S, Karran P. Vanillins-a novel family of DNA-PK inhibitors. Nucleic Acids Res 2003;31:5501-12.
58. Ismail IH, Mårtensson S, Moshinsky D, et al. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 2004;23:873-82.
59. Hollick JJ, Golding BT, Hardcastle IR, et al. 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK). Bioorg Med Chem Lett 2003;13:3083-6.
60. Leahy JJ, Golding BT, Griffin RJ, et al. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett 2004;14:6083-7.
61. Shinohara ET, Geng L, Tan J, et al. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 2005;65:4987-92.
62. Kashishian A, Douangpanya H, Clark D, et al. DNAdependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol Cancer Ther 2003;2:1257-64.
63. Nutley BP, Smith NF, Hayes A, et al. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br J Cancer 2005;93:1011-8.
64. Zhao Y, Thomas HD, Batey MA, et al. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 2006;66:5354-62.
65. Shaheen FS, Znojek P, Fisher A, et al. Targeting the DNA double strand break repair machinery in prostate cancer. PLoS ONE 2011;6:e20311.
66. Deriano L, Guipaud O, Merle-Béral H, et al. Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. Blood 2005;105:4776-83.
67. Azad A, Jackson S, Cullinane C, et al. Inhibition of DNAdependent protein kinase induces accelerated senescence in irradiated human cancer cells. Mol Cancer Res 2011;9:1696-707.
68. Zhuang W, Li B, Long L, et al. Knockdown of the DNAdependent protein kinase catalytic subunit radiosensitizes glioma-initiating cells by inducing autophagy. Brain Res 2011;1371:7-15.
69. Du L, Zhou LJ, Pan XJ, et al. Radiosensitization and growth inhibition of cancer cells mediated by an scFv antibody gene against DNA-PKcs in vitro and in vivo. Radiat Oncol 2010;5:70.
70. Ni X, Zhang Y, Ribas J, et al. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. J Clin Invest 2011;121:2383-90.
71. Li S, Takeda Y, Wragg S, et al. Modification of the ionizing radiation response in living cells by an scFv against the DNA-dependent protein kinase. Nucleic Acids Res 2003;31:5848-57.
72. Xiong H, Lee RJ, Haura EB, et al. Intranuclear Delivery of a Novel Antibody-Derived Radiosensitizer Targeting the DNA-Dependent Protein Kinase Catalytic Subunit. Int J Radiat Oncol Biol Phys 2011. [Epub ahead of print].
73. Xiong H, Li S, Yang Z, et al. coli expression of a soluble, active single-chain antibody variable fragment containing a nuclear localization signal. Protein Expr Purif 2009;66:172-80.
74. Sak A, Stuschke M, Wurm R, et al. Selective inactivation of DNA-dependent protein kinase with antisense oligodeoxynucleotides: consequences for the rejoining of radiation-induced DNA double-strand breaks and radiosensitivity of human cancer cell lines. Cancer Res. 2002;62:6621-4.
75. Collis SJ, Swartz MJ, Nelson WG, et al. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003;63:1550-4.
76. Bandyopadhyay D, Mandal M, Adam L, et al. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998;273:1568-73.
77. Toulany M, Kasten-Pisula U, Brammer I, et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair. Clin Cancer Res 2006;12:4119-26.
78. Das AK, Chen BP, Story MD, et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res 2007;67:5267-74.
79. Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 2011;71:1103-14.
80. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 2005;76:157-61.
81. Friedmann BJ, Caplin M, Savic B, et al. Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol Cancer Ther 2006;5:209-18.
82. Chan N, Bristow RG. "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. Clin Cancer Res 2010;16:4553-60.
83. Shaheen M, Allen C, Nickoloff JA, et al. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 2011;117:6074-82.
84. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011;5:387-93.
85. Veuger SJ, Curtin NJ, Richardson CJ, et al. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 2003;63:6008-15.
86. Veuger SJ, Curtin NJ, Smith GCM, et al. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004;23:7322-9.
87. Hisatomi T, Sueoka-Aragane N, Sato A, et al. NK314 potentiates antitumor activity with adult T-cell leukemialymphoma cells by inhibition of dual targets on topoisomerase II[alpha] and DNA-dependent protein kinase. Blood 2011;117:3575-84.
88. Mikusová V, Tichỳ A, Rezáčová M, et al. Mitoxantrone in Combination with a DNA-PK Inhibitor: Possible Therapy of Promyelocytic Leukaemia Resistant Forms. Folia Biol (Praha) 2011;57:200-5.
89. Willmore E, de Caux S, Sunter NJ, et al. A novel DNAdependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 2004;103:4659-65.
90. Davidson D, Grenier J, Martinez-Marignac V, et al. Effects of the novel DNA dependent protein kinase inhibitor, IC486241, on the DNA damage response to doxorubicin and cisplatin in breast cancer cells. Invest New Drugs. 2011. [Epub ahead of print].
91. Abe T, Ishiai M, Hosono Y, et al. KU70/80, DNAPKcs, and Artemis are essential for the rapid induction of apoptosis after massive DSB formation. Cell Signal 2008;20:1978-85.
92. Friesen C, Uhl M, Pannicke U, et al. DNA-ligase IV and DNA-protein kinase play a critical role in deficient caspases activation in apoptosis-resistant cancer cells by using doxorubicin. Mol Biol Cell 2008;19:3283-9.
93. Davidson D, Coulombe Y, Martinez-Marignac VL, et al. Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs 2012;30:1248-56.
94. Dejmek J, Iglehart JD, Lazaro JB. DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol Cancer Res 2009;7:581-91.
95. Stronach EA, Chen M, Maginn EN, et al. DNAPK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 2011;13:1069-80.
96. Jensen R, Glazer PM. Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions. Proc Natl Acad Sci USA 2004;101:6134-9.
97. Meador JA, Su Y, Ravanat J-L, et al. DNA-dependent protein kinase (DNA-PK)-deficient human glioblastoma cells are preferentially sensitized by Zebularine. Carcinogenesis 2010;31:184-91.
98. Zhu H, Gooderham NJ. Mechanisms of induction of cell cycle arrest and cell death by cryptolepine in human lung adenocarcinoma a549 cells. Toxicol Sci 2006;91:132-9.
99. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
100. Townsend DM, Shen H, Staros AL, et al. Efficacy of a glutathione S-transferase pi-activated prodrug in platinum-resistant ovarian cancer cells. Mol Cancer Ther 2002;1:1089-95.
101. Harima Y, Sawada S, Miyazaki Y, et al. Expression of Ku80 in cervical cancer correlates with response to radiotherapy and survival. Am J Clin Oncol 2003;26:e80-5.
102. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008;8:545-54.
103. Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Mol Oncol 2011;5:374-86.
104. Kirchgessner CU, Patil CK, Evans JW, et al. DNAdependent kinase (p350) as a candidate gene for the murine SCID defect. Science 1995;267:1178-83.
105. Dragoi AM, Fu X, Ivanov S, et al. DNA-PKcs, but not TLR9, is required for activation of Akt by CpG-DNA. EMBO J 2005;24:779-89.
106. Hazeki K, Kametani Y, Murakami H, et al. Phosphoinositide 3-kinasegamma controls the intracellular localization of CpG to limit DNA-PKcs-dependent IL-10 production in macrophages. PLoS ONE 2011;6:e26836.
107. Rajagopalan S, Moyle MW, Joosten I, et al. DNAPKcs controls an endosomal signaling pathway for a proinflammatory response by natural killer cells. Sci Signal 2010;3:ra14.
108. Becknell B, Caligiuri MA. Natural killer cells in innate immunity and cancer. J Immunother 2008;31:685-92.
109. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-7.